SCHEMBL2284247

SCHEMBL2284247

CC(=O)c1c(O)c2ccccc2[nH]c1=O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.69
ALDH1A1 P00352 4/20 0.65
MAPT P10636 4/20 0.65
GAA P10253 1/20 0.65
KMT2A Q03164 6/20 0.64
MEN1 O00255 5/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
NLRP3 Q96P20 1/20 0.64
IDE P14735 1/20 0.62
MPI P34949 1/20 0.62
CACNA1B Q00975 1/20 0.62
APBA1 Q02410 1/20 0.62
POLB P06746 2/20 0.60
RAB9A P51151 3/20 0.59
NPC1 O15118 2/20 0.58
RXFP1 Q9HBX9 1/20 0.58
DAO P14920 1/20 0.57
DDO Q99489 1/20 0.57
TDP1 Q9NUW8 1/20 0.57
LMNA P02545 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3985154 0.84 KDM4E (0.74) KDM4EALDH1A1MAPTGAAKMT2A
SCHEMBL29612172 0.83 KDM4E (0.69) KDM4EALDH1A1MAPTGAAKMT2A
SCHEMBL19952775 0.83 KDM4E (0.69) KDM4EALDH1A1MAPTGAAKMT2A
SCHEMBL1228041 0.83 KDM4E (0.62) KDM4EALDH1A1MAPTGAAKMT2A
SCHEMBL1622313 0.82 KDM4E (0.71) KDM4EALDH1A1MAPTGAAKMT2A
SCHEMBL30681958 0.82 KDM4E (0.71) KDM4EALDH1A1MAPTGAAKMT2A
SCHEMBL7827583 0.82 KDM5A (0.66) KDM4EALDH1A1MAPTGAAKMT2A
SCHEMBL15200787 0.82 KMT2A (0.72) KDM4EALDH1A1MAPTGAAKMT2A
SCHEMBL27948877 0.82 KDM4E (0.68) KDM4EALDH1A1MAPTGAAKMT2A
SCHEMBL13598046 0.82 KMT2A (0.75) KDM4EALDH1A1MAPTGAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103508950-B Containing 4-hydroxyl-2-quinolinones compound and the Synthesis and applications thereof of imine structure NANKAI UNIVERSITY (CN) 2016-04-20 CN disclosed
CN-103508950-A 4-hydroxy-2-quinolinone compounds containing imine structure, and preparation and application thereof UNIV NANKAI 2014-01-15 CN disclosed
US-8524729-B2 Cinnamoyl derivatives and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-09-03 US disclosed
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20070123521-A1 Cinnamoyl derivatives and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-05-31 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671950-A1 CINNAMOYL DERIVATIVES AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed
US-6861419-B2 Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. (US) 2005-03-01 US disclosed
EP-1324993-A2 SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF Cytovia, Inc. (US) 2003-07-09 EP disclosed
US-20020010169-A1 Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. 2002-01-24 US disclosed
WO-2001079187-A2 SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AND THEIR USE AS ACTIVATORS OF CASPASES CYTOVIA, INC. (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 KDM4E 2443/4885ALDH1A1 576/4885MAPT 4848/4885
US-20020010169-A1 Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP1, CASP14, CASP4 KDM4E 1882/4885ALDH1A1 832/4885MAPT 3104/4885
US-20070123521-A1 Cinnamoyl derivatives and use thereof CES2, EBP, CPT1A KDM4E 3010/4885ALDH1A1 31/4885MAPT 2597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.